Related Experiment Video
Updated: Mar 11, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent
Ana L M Batista de Carvalho1, Paula S C Medeiros1, Francisco M Costa2
1Unidade de I&D Química-Física Molecular, Department of Chemistry, University of Coimbra, Coimbra, Portugal.
Abstract:
The present work is aimed at evaluating the antitumour properties of a Pd(II) dinuclear complex with the biogenic polyamine spermine, by investigating: i) the anti-angiogenic and anti-migration properties of a Pd(II) dinuclear complex with spermine (Pd2Spm); ii) the anti-proliferative activity of Pd2Spm against a triple negative human breast carcinoma (MDA-MB-231); and finally iii) the putative interaction mediated by combination of Pd2Spm with Docetaxel. Anti-invasive (anti-angiogenic and anti-migratory) as well as anti-proliferative capacities were assessed, for different combination schemes and drug exposure times, using the CAM assay and VEGFR2 activity measurement, the MatrigelTM method and the SRB proliferation test. The results thus obtained evidence the ability of Pd2Spm to restrict angiogenesis and cell migration: Pd2Spm induced a marked inhibition of migration (43.8±12.2%), and a higher inhibition of angiogenesis (81.8±4.4% for total length values, at 4 μM) as compared to DTX at the clinical dosage 4x10-2 μM (26.4±14.4%; n = 4 to 11). Combination of Pd2Spm/DTX was more effective as anti-invasive and anti-proliferative than DTX or Pd2Spm in sole administration, which is compatible with the occurrence of synergism: for the anti-angiogenic effect, IC50(Pd2Spm/DTX) = 0.5/0.5x10-2 μM vs IC50(DTX) = 1.7x10-2 μM and IC50(Pd2Spm) = 1.6 μM. In conclusion, the reported effects of Pd2Spm on angiogenesis, migration and proliferation showed that this compound is a promising therapeutic agent against this type of breast cancer. Moreover, combined administration of Pd2Spm and DTX was found to trigger a substantial synergetic effect regarding angiogenesis inhibition as well as anti-migratory and anti-proliferative activities reinforcing the putative use of Pd(II) complexes in chemotherapeutic regimens. This is a significant outcome, aiming at the application of these combined strategies towards metastatic breast cancer (or other type of resistant cancers), justifying further studies that include pre-clinical trials.
Insights
A novel palladium(II) dinuclear complex with spermine (Pd2Spm) effectively inhibits angiogenesis and cancer cell migration. Combining Pd2Spm with Docetaxel shows synergistic anti-cancer effects, offering a promising strategy for breast cancer treatment.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Oncology
Background:
- Triple-negative breast cancer (TNBC) remains a significant therapeutic challenge.
- Developing novel anti-cancer agents with improved efficacy and reduced side effects is crucial.
- Palladium(II) complexes have shown potential as anti-tumour agents.
Purpose of the Study:
- To evaluate the anti-tumour properties of a Pd(II) dinuclear complex with spermine (Pd2Spm).
- To investigate the anti-angiogenic, anti-migratory, and anti-proliferative activities of Pd2Spm.
- To assess the potential synergistic interaction of Pd2Spm with Docetaxel (DTX) in treating breast cancer.
Main Methods:
- Chick Chorioallantoic Membrane (CAM) assay for angiogenesis.
- VEGFR2 activity measurement and MatrigelTM assay for cell migration.
- SRB proliferation assay against MDA-MB-231 triple-negative breast carcinoma cells.
- Combination studies with varying concentrations and exposure times of Pd2Spm and DTX.
Main Results:
- Pd2Spm demonstrated significant inhibition of angiogenesis (81.8±4.4%) and cell migration (43.8±12.2%).
- Pd2Spm exhibited potent anti-proliferative activity against MDA-MB-231 cells.
- The combination of Pd2Spm and DTX showed enhanced anti-invasive and anti-proliferative effects compared to individual treatments, indicating potential synergism.
- IC50 values revealed superior efficacy for the Pd2Spm/DTX combination in inhibiting angiogenesis.
Conclusions:
- Pd2Spm possesses promising anti-angiogenic, anti-migratory, and anti-proliferative properties, making it a potential therapeutic agent for breast cancer.
- The synergistic effect observed with Docetaxel highlights the potential of Pd(II) complexes in combination chemotherapy regimens.
- Further pre-clinical studies are warranted to explore the application of Pd2Spm and DTX combination therapy for metastatic or resistant cancers.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...